US Stock MarketDetailed Quotes

ITCI Intra-Cellular Therapies

Watchlist
  • 82.560
  • -0.670-0.80%
Close Jan 8 16:00 ET
  • 82.560
  • 0.0000.00%
Post 16:40 ET
8.75BMarket Cap-94.90P/E (TTM)

Intra-Cellular Therapies Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Intra-Cellular Therapies Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 8 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 198.775M--
--2024/Q4-- / 193.955M--
Oct 30, 20242024/Q3175.375M / 172.353M--
Aug 7, 20242024/Q2161.388M / 157.884M--
May 7, 20242024/Q1144.866M / 141.444M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 198.775M--
--2024/Q4-- / 193.955M--
Oct 30, 20242024/Q3175.375M / 172.353M--
Aug 7, 20242024/Q2161.388M / 157.884M--
May 7, 20242024/Q1144.866M / 141.444M--

Unlock Free Earnings Estimates

Intra-Cellular Therapies Earnings Reports

  • Intra-Cellular Therapies | 10-Q: Q3 2024 Earnings Report

    Oct 30, 2024 07:57 ET

  • Intra-Cellular Therapies | 8-K: INTRA-CELLULAR THERAPIES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE AND RAISES 2024 CAPLYTA SALES GUIDANCE

    Oct 30, 2024 07:47 ET

  • Intra-Cellular Therapies | 10-Q: Q2 2024 Earnings Report

    Aug 7, 2024 07:56 ET

  • Intra-Cellular Therapies | 8-K: INTRA-CELLULAR THERAPIES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE AND RAISES 2024 CAPLYTA SALES GUIDANCE

    Aug 7, 2024 07:51 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 7, 2025

    Strong Buy

    • Buy

      85.71%

    • Hold

      14.29%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data